InvestorsHub Logo
Followers 20
Posts 2618
Boards Moderated 0
Alias Born 01/27/2022

Re: None

Sunday, 04/16/2023 7:55:56 PM

Sunday, April 16, 2023 7:55:56 PM

Post# of 426485
God damn, this MO issue just will NOT go away.

The way I see it, the one problem is (despite biomarkers not having a direct correlation to outcomes) the biomarker issue between REDUCE-It and STRENGTH. In STRENGTH, biomarkers in the control arm remained flat. In REDUCE-It, biomarkers went UP in the control arm. I'm not sure how you explain that away, because that is exactly what docs are latching on to.

I think Amarin needs to do a better job of articulating the studies done on the placebos.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News